FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148933215> ?p ?o ?g. }

• W2148933215 endingPage "218" @default.
• W2148933215 startingPage "208" @default.
• W2148933215 abstract "The recognition that few human diseases are thoroughly addressed by mono-specific, monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics with additional specificities and enhanced activity. Historically, efforts to engineer additional antigen recognition into molecules have relied predominantly on the reformatting of immunoglobulin domains. In this report we describe a series of fully functional mAbs to which additional specificities have been imparted through the recombinant fusion of relatively short polypeptides sequences. The sequences are selected for binding to a particular target from combinatorial libraries that express linear, disulfide-constrained, or domain-based structures. The potential for fusion of peptides to the N- and C- termini of both the heavy and light chains affords the bivalent expression of up to four different peptides. The resulting molecules, called zybodies, can gain up to four additional specificities, while retaining the original functionality and specificity of the scaffold antibody. We explore the use of two clinically significant oncology antibodies, trastuzumab and cetuximab, as zybody scaffolds and demonstrate functional enhancements in each case. The affect of fusion position on both peptide and scaffold function is explored, and penta-specific zybodies are demonstrated to simultaneously engage five targets (ErbB2, EGFR, IGF-1R, Ang2 and integrin αvβ3). Bispecific, trastuzumab-based zybodies targeting ErbB2 and Ang2 are shown to exhibit superior efficacy to trastuzumab in an angiogenesis-dependent xenograft tumor model. A cetuximab-based bispecific zybody that targeting EGFR and ErbB3 simultaneously disrupted multiple intracellular signaling pathways; inhibited tumor cell proliferation; and showed efficacy superior to that of cetuximab in a xenograft tumor model." @default.
• W2148933215 created "2016-06-24" @default.
• W2148933215 creator A5002491364 @default.
• W2148933215 creator A5003601809 @default.
• W2148933215 creator A5005167916 @default.
• W2148933215 creator A5008195024 @default.
• W2148933215 creator A5010146238 @default.
• W2148933215 creator A5013869729 @default.
• W2148933215 creator A5017032493 @default.
• W2148933215 creator A5019260009 @default.
• W2148933215 creator A5027904289 @default.
• W2148933215 creator A5036858883 @default.
• W2148933215 creator A5043609061 @default.
• W2148933215 creator A5064634030 @default.
• W2148933215 creator A5066851101 @default.
• W2148933215 creator A5067371923 @default.
• W2148933215 creator A5067949575 @default.
• W2148933215 creator A5076188773 @default.
• W2148933215 creator A5076665618 @default.
• W2148933215 creator A5077759207 @default.
• W2148933215 creator A5078761190 @default.
• W2148933215 creator A5081626384 @default.
• W2148933215 creator A5082452338 @default.
• W2148933215 date "2013-03-01" @default.
• W2148933215 modified "2023-09-26" @default.
• W2148933215 title "Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides" @default.
• W2148933215 cites W1921660070 @default.
• W2148933215 cites W1982762974 @default.
• W2148933215 cites W1992423971 @default.
• W2148933215 cites W1992703637 @default.
• W2148933215 cites W1993639035 @default.
• W2148933215 cites W2012536704 @default.
• W2148933215 cites W2018918678 @default.
• W2148933215 cites W2019176391 @default.
• W2148933215 cites W2019183242 @default.
• W2148933215 cites W2021855052 @default.
• W2148933215 cites W2024298562 @default.
• W2148933215 cites W2038846160 @default.
• W2148933215 cites W2080162976 @default.
• W2148933215 cites W2085690948 @default.
• W2148933215 cites W2086911835 @default.
• W2148933215 cites W2095724306 @default.
• W2148933215 cites W2095911270 @default.
• W2148933215 cites W2097478805 @default.
• W2148933215 cites W2111578514 @default.
• W2148933215 cites W2111823261 @default.
• W2148933215 cites W2113479218 @default.
• W2148933215 cites W2115759102 @default.
• W2148933215 cites W2121160430 @default.
• W2148933215 cites W2123170601 @default.
• W2148933215 cites W2124114323 @default.
• W2148933215 cites W2137950260 @default.
• W2148933215 cites W2142636897 @default.
• W2148933215 cites W2143738177 @default.
• W2148933215 cites W2148203764 @default.
• W2148933215 cites W2151464858 @default.
• W2148933215 cites W2154946742 @default.
• W2148933215 cites W2160705247 @default.
• W2148933215 cites W2163065611 @default.
• W2148933215 cites W2164953211 @default.
• W2148933215 cites W2166199281 @default.
• W2148933215 cites W2168272067 @default.
• W2148933215 cites W2169344919 @default.
• W2148933215 doi "https://doi.org/10.4161/mabs.23043" @default.
• W2148933215 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3893231" @default.
• W2148933215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23575268" @default.
• W2148933215 hasPublicationYear "2013" @default.
• W2148933215 type Work @default.
• W2148933215 sameAs 2148933215 @default.
• W2148933215 citedByCount "41" @default.
• W2148933215 countsByYear W21489332152013 @default.
• W2148933215 countsByYear W21489332152014 @default.
• W2148933215 countsByYear W21489332152015 @default.
• W2148933215 countsByYear W21489332152016 @default.
• W2148933215 countsByYear W21489332152017 @default.
• W2148933215 countsByYear W21489332152018 @default.
• W2148933215 countsByYear W21489332152019 @default.
• W2148933215 countsByYear W21489332152020 @default.
• W2148933215 countsByYear W21489332152021 @default.
• W2148933215 crossrefType "journal-article" @default.
• W2148933215 hasAuthorship W2148933215A5002491364 @default.
• W2148933215 hasAuthorship W2148933215A5003601809 @default.
• W2148933215 hasAuthorship W2148933215A5005167916 @default.
• W2148933215 hasAuthorship W2148933215A5008195024 @default.
• W2148933215 hasAuthorship W2148933215A5010146238 @default.
• W2148933215 hasAuthorship W2148933215A5013869729 @default.
• W2148933215 hasAuthorship W2148933215A5017032493 @default.
• W2148933215 hasAuthorship W2148933215A5019260009 @default.
• W2148933215 hasAuthorship W2148933215A5027904289 @default.
• W2148933215 hasAuthorship W2148933215A5036858883 @default.
• W2148933215 hasAuthorship W2148933215A5043609061 @default.
• W2148933215 hasAuthorship W2148933215A5064634030 @default.
• W2148933215 hasAuthorship W2148933215A5066851101 @default.
• W2148933215 hasAuthorship W2148933215A5067371923 @default.
• W2148933215 hasAuthorship W2148933215A5067949575 @default.
• W2148933215 hasAuthorship W2148933215A5076188773 @default.
• W2148933215 hasAuthorship W2148933215A5076665618 @default.
• W2148933215 hasAuthorship W2148933215A5077759207 @default.

• next